Systematic reviews suggest that GLP-1 RAs may, in fact, exert neuroprotective effects in diabetes-related neurological complications, although recent pharmacovigilance analyses have identified various neurological adverse events temporally associated with GLP-1 RAs, emphasizing the need for continued surveillance [11]. Here, GLP1R is linked to diabetes mellitus.